32
Assessment/Diagnosis
Lymphedema
➤ This chronic, progressive disorder of the lymphatic circulation is
characterized by the accumulation of protein-rich interstitial fluid
due to impaired lymphatic transport. In individuals with obesity,
excess subcutaneous fat compresses lymphatic vessels, promoting
chronic inflammation mediated by macrophage infiltration and
proinflammatory cytokines. This leads to lymphatic dysfunction,
tissue fibrosis, and ongoing fluid retention, which perpetuates
lymphatic failure and tissue remodeling.
Risk Factors
• Lymphedema in obesity is influenced by modifiable risk factors,
including elevated BMI (particularly ≥50 kg/m²), a sedentary lifestyle
that reduces muscle pump efficacy, chronic venous insufficiency,
recurrent cellulitis, and impaired skin hygiene due to functional
limitations. Nonmodifiable risks include genetic predisposition
(e.g., primary lymphedema), prior oncologic surgery or radiation,
congenital syndromes like Turner or Noonan, female sex, and older
age. Notably, class III obesity markedly increases lymphedema risk
even without prior surgical or oncologic history, with BMI identified
as the strongest independent predictor in cancer-free populations.
➤ Clinical Manifestations
• Lymphedema typically presents with a gradual onset and
advances through three clinical stages:
▶ Stage 0 (subclinical): impaired lymphatic transport without
visible swelling.
▶ Stage I (reversible): soft, pitting edema relieved with elevation.
▶ Stage II (irreversible): nonpitting edema, f ibrotic skin changes,
and poor response to elevation, culminating in severe
lymphostatic elephantiasis.
▶ Stage III: pronounced skin thickening, hyperkeratosis, and
infection risk.
• In obesity, lymphedema commonly affects the lower extremities,
abdominal pannus, or genitalia; a positive Stemmer sign indicates
established disease, and chronic lymphatic congestion significantly
increases susceptibility to recurrent cellulitis and lymphangitis.
